BlackRock Institutional Trust Company N.A. raised its position in Bluebird Bio Inc. (NASDAQ:BLUE) by 3.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 935,722 shares of the company’s stock after buying an additional 32,756 shares during the period. BlackRock Institutional Trust Company N.A. owned approximately 2.52% of Bluebird Bio worth $63,423,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. BlackRock Group LTD boosted its stake in shares of Bluebird Bio by 253.6% in the third quarter. BlackRock Group LTD now owns 77,905 shares of the company’s stock worth $5,280,000 after buying an additional 55,875 shares during the period. Rhumbline Advisers boosted its stake in shares of Bluebird Bio by 4.4% in the third quarter. Rhumbline Advisers now owns 47,412 shares of the company’s stock worth $3,214,000 after buying an additional 2,011 shares during the period. Teachers Advisors LLC boosted its stake in shares of Bluebird Bio by 101.2% in the third quarter. Teachers Advisors LLC now owns 151,646 shares of the company’s stock worth $10,279,000 after buying an additional 76,290 shares during the period. BlackRock Fund Advisors boosted its position in Bluebird Bio by 6.4% in the third quarter. BlackRock Fund Advisors now owns 1,475,395 shares of the company’s stock worth $100,002,000 after buying an additional 89,166 shares during the last quarter. Finally, BlackRock Inc. boosted its position in Bluebird Bio by 238.1% in the third quarter. BlackRock Inc. now owns 24,148 shares of the company’s stock worth $1,637,000 after buying an additional 17,005 shares during the last quarter.
Shares of Bluebird Bio Inc. (NASDAQ:BLUE) opened at 67.60 on Thursday. Bluebird Bio Inc. has a 52 week low of $35.37 and a 52 week high of $79.70. The firm has a 50 day moving average of $67.32 and a 200 day moving average of $59.33. The firm’s market cap is $2.52 billion.
Bluebird Bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, November 2nd. The company reported ($2.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.59) by $0.48. The company earned $1.55 million during the quarter, compared to analyst estimates of $1.82 million. Bluebird Bio had a negative return on equity of 30.79% and a negative net margin of 3,941.72%. The business’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.18) earnings per share. Equities analysts predict that Bluebird Bio Inc. will post ($7.02) earnings per share for the current fiscal year.
A number of equities analysts have weighed in on the stock. Cantor Fitzgerald reissued a “sell” rating and issued a $37.00 price objective on shares of Bluebird Bio in a research report on Thursday, November 3rd. Wedbush reissued an “outperform” rating and issued a $95.00 price objective on shares of Bluebird Bio in a research report on Wednesday, November 23rd. Bank of America Corp. reissued a “neutral” rating and issued a $68.00 price objective on shares of Bluebird Bio in a research report on Sunday, December 4th. Leerink Swann upped their price objective on shares of Bluebird Bio from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Thursday, December 1st. Finally, Janney Montgomery Scott reissued a “buy” rating on shares of Bluebird Bio in a research report on Thursday, November 24th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $84.90.
In other Bluebird Bio news, insider Jason Cole sold 549 shares of the firm’s stock in a transaction on Thursday, January 5th. The shares were sold at an average price of $67.10, for a total value of $36,837.90. Following the sale, the insider now directly owns 9,389 shares in the company, valued at approximately $630,001.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 3.50% of the stock is currently owned by company insiders.
About Bluebird Bio
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bluebird Bio Inc. (NASDAQ:BLUE).